-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Following GE's confirmation of "one to three", on November 12, another medical equipment giant Johnson & Johnson also announced a split plan
.
.
Johnson & Johnson plans to spin off its consumer health business and go public independently.
Its well-known brands such as Neutrogena, Aveeno, Listerine and Band-Aids will be managed by this new company
.
The name of the new company has not yet been determined
.
Its well-known brands such as Neutrogena, Aveeno, Listerine and Band-Aids will be managed by this new company
.
The name of the new company has not yet been determined
.
The pharmaceutical and medical equipment businesses with advanced technologies such as robotics and artificial intelligence retain the name Johnson & Johnson
.
CEO Alex Gorsky, who has been in charge of Johnson & Johnson for nearly ten years, will continue to serve as executive chairman until January 3, 2022, when Joaquin Duato, vice chairman of the executive committee, will take over
.
.
CEO Alex Gorsky, who has been in charge of Johnson & Johnson for nearly ten years, will continue to serve as executive chairman until January 3, 2022, when Joaquin Duato, vice chairman of the executive committee, will take over
.
The split plan will be completed in the next 18 to 24 months
.
After the announcement, Johnson & Johnson's stock price rose nearly 3% in pre-market trading
.
.
After the announcement, Johnson & Johnson's stock price rose nearly 3% in pre-market trading
.
The current CEO Alex Gorsky said: "After a thorough review, the board and management team believe that the divestiture of the consumer health business is the best way to accelerate our service to patients, consumers and healthcare professionals, create opportunities for the global team, and drive profitable growth.
.
And, most importantly, to improve health care outcomes for people all over the world
.
"
.
And, most importantly, to improve health care outcomes for people all over the world
.
"
Johnson & Johnson was founded in 1886 and is headquartered in New Jersey, USA.
It is divided into three business segments: medical devices, pharmaceuticals and consumer products
.
It has more than 260 operating companies in 60 countries and regions and more than 130,000 employees worldwide
.
It is divided into three business segments: medical devices, pharmaceuticals and consumer products
.
It has more than 260 operating companies in 60 countries and regions and more than 130,000 employees worldwide
.
In 1985, as one of the first multinational companies to enter the Chinese market since the reform and opening up, Johnson & Johnson established Xi'an Janssen Pharmaceutical Co.
, Ltd.
in China
.
, Ltd.
in China
.
In 1994, Johnson & Johnson (China) Medical Equipment Co.
, Ltd.
was established, mainly engaged in medical equipment related industries in China
.
, Ltd.
was established, mainly engaged in medical equipment related industries in China
.
In 2020, Johnson & Johnson's global revenue is 82.
6 billion U.
S.
dollars
.
6 billion U.
S.
dollars
.
On October 19 this year, Johnson & Johnson announced its 2021 Q3 performance: Q3 sales were 23.
338 billion U.
S.
dollars, an increase of 10.
7% year-on-year; net profit was 3.
667 billion U.
S.
dollars, a year-on-year increase of 3.
2%——
338 billion U.
S.
dollars, an increase of 10.
7% year-on-year; net profit was 3.
667 billion U.
S.
dollars, a year-on-year increase of 3.
2%——
Consumer health business revenue was US$3.
7 billion, a year-on-year increase of 4.
1%;
7 billion, a year-on-year increase of 4.
1%;
Pharmaceutical business revenue was US$12.
994 billion, a year-on-year increase of 13.
2%, of which sales of new crown vaccines were US$502 million;
994 billion, a year-on-year increase of 13.
2%, of which sales of new crown vaccines were US$502 million;
The medical device business revenue was US$6.
644 billion, a year-on-year increase of 7.
0%
.
644 billion, a year-on-year increase of 7.
0%
.
Among them, the income of various segments of medical equipment business is as follows:
Intervention solution revenue was US$957 million, a year-on-year increase of 13.
2%;
2%;
Orthopedics revenue was US$2.
093 billion, a year-on-year decrease of 0.
3%.
Among them, the hip, knee, and trauma businesses all increased, and the spine, sports and other revenue decreased by 6.
3%;
093 billion, a year-on-year decrease of 0.
3%.
Among them, the hip, knee, and trauma businesses all increased, and the spine, sports and other revenue decreased by 6.
3%;
Surgical revenue was US$2.
405 billion, a year-on-year increase of 10.
2%;
405 billion, a year-on-year increase of 10.
2%;
Vision care revenue was US$1.
189 billion, a year-on-year increase of 10.
0%
.
189 billion, a year-on-year increase of 10.
0%
.
In recent years, Johnson & Johnson has also continued to expand its deployment in the field of surgical robots and orthopedics
.
.
In early 2018, Johnson & Johnson acquired Orthotaxy, a French private surgical technology software development company, and obtained the VELYS platform technology
.
.
In September 2018, Johnson & Johnson acquired Emerging Implant Technologies (EIT), a German manufacturer of 3D printed spinal implants
.
.
In February 2019, Johnson & Johnson acquired Auris Health for US$3.
4 billion
.
Its product is the Monarch platform, a robotic system for lung cancer puncture, which has been approved by the FDA for bronchoscopy diagnosis and treatment procedures
.
4 billion
.
Its product is the Monarch platform, a robotic system for lung cancer puncture, which has been approved by the FDA for bronchoscopy diagnosis and treatment procedures
.
In September 2019, Johnson & Johnson acquired the pelvic surgery navigation software developed by JointPoint, a surgical navigation technology company
.
.
In December 2019, Johnson & Johnson acquired the remaining shares of Verb Surgical, which was previously co-founded with Google, and took over the robotic surgery business of Verily, a Google subsidiary
.
.
In January 2020, Johnson & Johnson's orthopedic surgical robot product VELYS™ was approved by the FDA for marketing
.
.
In November 2020, Johnson & Johnson released the Ottava surgical robot equipped with six robotic arms
.
.
In August 2021, Johnson & Johnson Innovations (JJDC) and Almeda Ventures led the investment and raised USD 13 million from FlexDex Surgica to fund the development of FlexDex Surgical's next-generation advanced laparoscopic devices with robotic functions
.
.
In September 2021, Johnson & Johnson and TINAVI, a Chinese orthopedic robotics company , signed a strategic cooperation with Shanghai Renji Hospital to establish a clinical technology application center for robot-assisted spinal surgery
.
.
"The general trend of the world, divided for a long time must be united, and together for a long time must be divided
.
"
.
"
With the changes of the times, "big Mac" enterprises that span many fields have begun to quietly step down the stage of history
.
Between division and integration, the focus of business on core capabilities and the concentration of resources on core business is the only magic weapon to maintain competitive advantage and efficient operation
.
.
Between division and integration, the focus of business on core capabilities and the concentration of resources on core business is the only magic weapon to maintain competitive advantage and efficient operation
.
In the past, Siemens Medical went public independently in 2018.
Later, Philips divested the small home appliance business and GE divided it into three.
Now Johnson & Johnson has also announced its plan.
In the prevailing wave of splitting of global business giants, who will be the next one?
Later, Philips divested the small home appliance business and GE divided it into three.
Now Johnson & Johnson has also announced its plan.
In the prevailing wave of splitting of global business giants, who will be the next one?
Following GE's confirmation of "one to three", on November 12, another medical equipment giant Johnson & Johnson also announced a split plan
.
.
Johnson & Johnson plans to spin off its consumer health business and go public independently.
Its well-known brands such as Neutrogena, Aveeno, Listerine and Band-Aids will be managed by this new company
.
The name of the new company has not yet been determined
.
Its well-known brands such as Neutrogena, Aveeno, Listerine and Band-Aids will be managed by this new company
.
The name of the new company has not yet been determined
.
The pharmaceutical and medical equipment businesses with advanced technologies such as robotics and artificial intelligence retain the name Johnson & Johnson
.
CEO Alex Gorsky, who has been in charge of Johnson & Johnson for nearly ten years, will continue to serve as executive chairman until January 3, 2022, when Joaquin Duato, vice chairman of the executive committee, will take over
.
.
CEO Alex Gorsky, who has been in charge of Johnson & Johnson for nearly ten years, will continue to serve as executive chairman until January 3, 2022, when Joaquin Duato, vice chairman of the executive committee, will take over
.
The split plan will be completed in the next 18 to 24 months
.
After the announcement, Johnson & Johnson's stock price rose nearly 3% in pre-market trading
.
.
After the announcement, Johnson & Johnson's stock price rose nearly 3% in pre-market trading
.
The current CEO Alex Gorsky said: "After a thorough review, the board and management team believe that the divestiture of the consumer health business is the best way to accelerate our service to patients, consumers and healthcare professionals, create opportunities for the global team, and drive profitable growth.
.
And, most importantly, to improve health care outcomes for people all over the world
.
"
.
And, most importantly, to improve health care outcomes for people all over the world
.
"
Johnson & Johnson was founded in 1886 and is headquartered in New Jersey, USA.
It is divided into three business segments: medical devices, pharmaceuticals and consumer products
.
It has more than 260 operating companies in 60 countries and regions and more than 130,000 employees worldwide
.
It is divided into three business segments: medical devices, pharmaceuticals and consumer products
.
It has more than 260 operating companies in 60 countries and regions and more than 130,000 employees worldwide
.
In 1985, as one of the first multinational companies to enter the Chinese market since the reform and opening up, Johnson & Johnson established Xi'an Janssen Pharmaceutical Co.
, Ltd.
in China
.
, Ltd.
in China
.
In 1994, Johnson & Johnson (China) Medical Equipment Co.
, Ltd.
was established, mainly engaged in medical equipment related industries in China
.
, Ltd.
was established, mainly engaged in medical equipment related industries in China
.
In 2020, Johnson & Johnson's global revenue is 82.
6 billion U.
S.
dollars
.
6 billion U.
S.
dollars
.
On October 19 this year, Johnson & Johnson announced its 2021 Q3 performance: Q3 sales were 23.
338 billion U.
S.
dollars, an increase of 10.
7% year-on-year; net profit was 3.
667 billion U.
S.
dollars, a year-on-year increase of 3.
2%——
338 billion U.
S.
dollars, an increase of 10.
7% year-on-year; net profit was 3.
667 billion U.
S.
dollars, a year-on-year increase of 3.
2%——
Consumer health business revenue was US$3.
7 billion, a year-on-year increase of 4.
1%;
7 billion, a year-on-year increase of 4.
1%;
Pharmaceutical business revenue was US$12.
994 billion, a year-on-year increase of 13.
2%, of which sales of new crown vaccines were US$502 million;
994 billion, a year-on-year increase of 13.
2%, of which sales of new crown vaccines were US$502 million;
The medical device business revenue was US$6.
644 billion, a year-on-year increase of 7.
0%
.
644 billion, a year-on-year increase of 7.
0%
.
Among them, the income of various segments of medical equipment business is as follows:
Intervention solution revenue was US$957 million, a year-on-year increase of 13.
2%;
2%;
Orthopedics revenue was US$2.
093 billion, a year-on-year decrease of 0.
3%.
Among them, the hip, knee, and trauma businesses all increased, and the spine, sports and other revenue decreased by 6.
3%;
093 billion, a year-on-year decrease of 0.
3%.
Among them, the hip, knee, and trauma businesses all increased, and the spine, sports and other revenue decreased by 6.
3%;
Surgical revenue was US$2.
405 billion, a year-on-year increase of 10.
2%;
405 billion, a year-on-year increase of 10.
2%;
Vision care revenue was US$1.
189 billion, a year-on-year increase of 10.
0%
.
189 billion, a year-on-year increase of 10.
0%
.
In recent years, Johnson & Johnson has also continued to expand its deployment in the field of surgical robots and orthopedics
.
.
In early 2018, Johnson & Johnson acquired Orthotaxy, a French private surgical technology software development company, and obtained the VELYS platform technology
.
.
In September 2018, Johnson & Johnson acquired Emerging Implant Technologies (EIT), a German manufacturer of 3D printed spinal implants
.
.
In February 2019, Johnson & Johnson acquired Auris Health for US$3.
4 billion
.
Its product is the Monarch platform, a robotic system for lung cancer puncture, which has been approved by the FDA for bronchoscopy diagnosis and treatment procedures
.
4 billion
.
Its product is the Monarch platform, a robotic system for lung cancer puncture, which has been approved by the FDA for bronchoscopy diagnosis and treatment procedures
.
In September 2019, Johnson & Johnson acquired the pelvic surgery navigation software developed by JointPoint, a surgical navigation technology company
.
.
In December 2019, Johnson & Johnson acquired the remaining shares of Verb Surgical, which was previously co-founded with Google, and took over the robotic surgery business of Verily, a Google subsidiary
.
.
In January 2020, Johnson & Johnson's orthopedic surgical robot product VELYS™ was approved by the FDA for marketing
.
.
In November 2020, Johnson & Johnson released the Ottava surgical robot equipped with six robotic arms
.
.
In August 2021, Johnson & Johnson Innovations (JJDC) and Almeda Ventures led the investment and raised USD 13 million from FlexDex Surgica to fund the development of FlexDex Surgical's next-generation advanced laparoscopic devices with robotic functions
.
.
In September 2021, Johnson & Johnson and TINAVI, a Chinese orthopedic robotics company , signed a strategic cooperation with Shanghai Renji Hospital to establish a clinical technology application center for robot-assisted spinal surgery
.
.
"The general trend of the world, divided for a long time must be united, and together for a long time must be divided
.
"
.
"
With the changes of the times, "big Mac" enterprises that span many fields have begun to quietly step down the stage of history
.
Between division and integration, the focus of business on core capabilities and the concentration of resources on core business is the only magic weapon to maintain competitive advantage and efficient operation
.
.
Between division and integration, the focus of business on core capabilities and the concentration of resources on core business is the only magic weapon to maintain competitive advantage and efficient operation
.
In the past, Siemens Medical went public independently in 2018.
Later, Philips divested the small home appliance business and GE divided it into three.
Now Johnson & Johnson has also announced its plan.
In the prevailing wave of splitting of global business giants, who will be the next one?
Later, Philips divested the small home appliance business and GE divided it into three.
Now Johnson & Johnson has also announced its plan.
In the prevailing wave of splitting of global business giants, who will be the next one?
Following GE's confirmation of "one to three", on November 12, another medical equipment giant Johnson & Johnson also announced a split plan
.
.
，Neutrogena、Aveeno、ListerineBand-Aids
。
。
。
。
。CEO Alex Gorsky202213，Joaquin Duato
。
1824
。，3%
。
。，3%
。
CEO Alex Gorsky：“，，、，，
。，，
。”
。，，
。”
1886，，、
。60260，13
。
。60260，13
。
1985，，
。
。
In 1994, Johnson & Johnson (China) Medical Equipment Co.
, Ltd.
was established, mainly engaged in medical equipment related industries in China
.
, Ltd.
was established, mainly engaged in medical equipment related industries in China
.
In 2020, Johnson & Johnson's global revenue is 82.
6 billion U.
S.
dollars
.
6 billion U.
S.
dollars
.
On October 19 this year, Johnson & Johnson announced its 2021 Q3 performance: Q3 sales were 23.
338 billion U.
S.
dollars, an increase of 10.
7% year-on-year; net profit was 3.
667 billion U.
S.
dollars, a year-on-year increase of 3.
2%——
338 billion U.
S.
dollars, an increase of 10.
7% year-on-year; net profit was 3.
667 billion U.
S.
dollars, a year-on-year increase of 3.
2%——
Consumer health business revenue was US$3.
7 billion, a year-on-year increase of 4.
1%;
7 billion, a year-on-year increase of 4.
1%;
Pharmaceutical business revenue was US$12.
994 billion, a year-on-year increase of 13.
2%, of which sales of new crown vaccines were US$502 million;
994 billion, a year-on-year increase of 13.
2%, of which sales of new crown vaccines were US$502 million;
The medical device business revenue was US$6.
644 billion, a year-on-year increase of 7.
0%
.
Medical equipment medical equipment medical equipment644 billion, a year-on-year increase of 7.
0%
.
Among them, the income of various segments of medical equipment business is as follows:
Intervention solution revenue was US$957 million, a year-on-year increase of 13.
2%;
2%;
Orthopedics revenue was US$2.
093 billion, a year-on-year decrease of 0.
3%.
Among them, the hip, knee, and trauma businesses all increased, and the spine, sports and other revenue decreased by 6.
3%;
093 billion, a year-on-year decrease of 0.
3%.
Among them, the hip, knee, and trauma businesses all increased, and the spine, sports and other revenue decreased by 6.
3%;
Surgical revenue was US$2.
405 billion, a year-on-year increase of 10.
2%;
405 billion, a year-on-year increase of 10.
2%;
Vision care revenue was US$1.
189 billion, a year-on-year increase of 10.
0%
.
189 billion, a year-on-year increase of 10.
0%
.
In recent years, Johnson & Johnson has also continued to expand its deployment in the field of surgical robots and orthopedics
.
.
In early 2018, Johnson & Johnson acquired Orthotaxy, a French private surgical technology software development company, and obtained the VELYS platform technology
.
.
In September 2018, Johnson & Johnson acquired Emerging Implant Technologies (EIT), a German manufacturer of 3D printed spinal implants
.
.
In February 2019, Johnson & Johnson acquired Auris Health for US$3.
4 billion
.
Its product is the Monarch platform, a robotic system for lung cancer puncture, which has been approved by the FDA for bronchoscopy diagnosis and treatment procedures
.
4 billion
.
Its product is the Monarch platform, a robotic system for lung cancer puncture, which has been approved by the FDA for bronchoscopy diagnosis and treatment procedures
.
In September 2019, Johnson & Johnson acquired the pelvic surgery navigation software developed by JointPoint, a surgical navigation technology company
.
.
In December 2019, Johnson & Johnson acquired the remaining shares of Verb Surgical, which was previously co-founded with Google, and took over the robotic surgery business of Verily, a Google subsidiary
.
.
In January 2020, Johnson & Johnson's orthopedic surgical robot product VELYS™ was approved by the FDA for marketing
.
.
In November 2020, Johnson & Johnson released the Ottava surgical robot equipped with six robotic arms
.
.
In August 2021, Johnson & Johnson Innovations (JJDC) and Almeda Ventures led the investment and raised USD 13 million from FlexDex Surgica to fund the development of FlexDex Surgical's next-generation advanced laparoscopic devices with robotic functions
.
.
In September 2021, Johnson & Johnson and TINAVI, a Chinese orthopedic robotics company , signed a strategic cooperation with Shanghai Renji Hospital to establish a clinical technology application center for robot-assisted spinal surgery
.
Hospital hospital hospital.
"The general trend of the world, divided for a long time must be united, and together for a long time must be divided
.
"
.
"
With the changes of the times, "big Mac" enterprises that span many fields have begun to quietly step down the stage of history
.
Between division and integration, the focus of business on core capabilities and the concentration of resources on core business is the only magic weapon to maintain competitive advantage and efficient operation
.
Enterprise business enterprise.
Between division and integration, the focus of business on core capabilities and the concentration of resources on core business is the only magic weapon to maintain competitive advantage and efficient operation
.
In the past, Siemens Medical went public independently in 2018.
Later, Philips divested the small home appliance business and GE divided it into three.
Now Johnson & Johnson has also announced its plan.
In the prevailing wave of splitting of global business giants, who will be the next one?
Later, Philips divested the small home appliance business and GE divided it into three.
Now Johnson & Johnson has also announced its plan.
In the prevailing wave of splitting of global business giants, who will be the next one?
